What are the limitations of the vienna prediction model?

While the vienna prediction model is highly validated, it should not replace clinical judgment. OpiCalc provides the latest evidence-based limitations for the vienna prediction model to ensure safe bedside use and optimal diagnostic accuracy.

How does the vienna prediction model compare to other hematology scores?

The vienna prediction model is a gold-standard diagnostic tool. OpiCalc provides side-by-side clinical guidance to help clinicians choose the most specific evidence-based tool for their patient's presentation.

Is the vienna prediction model free to use?

Yes. OpiCalc provides the vienna prediction model completely ad-free and optimized for mobile bedside use, ensuring you can calculate medical risk swiftly and without distraction.

OpiCalc

927 Clinical Tools

OpiCalc

4Ts Score (HIT)aaIPI (Age-adjusted IPI)ABC Score (Massive Transfusion)Absolute Neutrophil Count Age-adjusted D-dimer Threshold aGvHD Grading (Glucksberg/MAGIC)AL Amyloidosis Staging (Mayo)Anti-Xa Monitoring Interpreter Antiphospholipid Syndrome Classification Binet / Rai Staging (CML)Blood Volume Calculator Caprini VTE Risk CISNE Score CLL-IPI Coombs-Negative Haemolysis Checklist Corrected Reticulocyte Count CRS Grading (ASTCT 2019)DAT Interpretation Algorithm Deauville Score Interpreter DIC Score (ISTH)DIPSS (MF)DIPSS-Plus (MF)DOAC Dose Selector DOAC Renal Dose Adjustment DRI (Disease Risk Index)Durie-Salmon Staging (historical)EBMT Risk Score ELN 2022 AML Risk Classification ELTS Score (CML)England & Fraser Index EUTOS Score (CML)Expected Hb Rise per RBC Unit Factor Inhibitor Bethesda Titre Interpreter Febrile Neutropaenia Risk (MASCC)Fibrinogen Replacement FLIPI (Follicular Lymphoma IPI)FLIPI-2 French TTP Score GAPSS (Global APS Score)Haemophilia Severity Classification HbS Percentage Target Calculator HCT-CI (Comorbidity Index)HEP Score Heparin Nomogram (Weight-based)Hepatic Iron Index HERDOO2 Rule HFE Haemochromatosis Risk Estimator ICANS Grading (ASTCT 2019)IMWG Response Criteria (Myeloma)IPI (International Prognostic Index)IPSID / Lugano Classification IPSS-M (Molecular IPSS)IPSS-R (Revised IPSS for MDS)Iron Deficit Calculator (Ganzoni Formula)ISS (Myeloma)ISTH Bleeding Assessment Tool (BAT)ISTH Non-Overt DIC Score ITP Bleeding Score iwCLL Response Criteria (2018)IWG ITP Response Criteria JAK2V617F Allele Burden Interpreter Karnofsky Performance Scale Leucostasis Risk Threshold Lupus Anticoagulant (LAC) Reporting Framework MAGIC aGvHD Biomarker Score MCV-based Anaemia Algorithm Mentzer Index MIPI (MCL IPI)MIPSS70+ v2.0 (MF)Mixing Study Interpretation MRD Assessment Threshold Interpreter mSMART 3.0 (Myeloma)MTP Activation Criteria NCCN-IPI NIH Chronic GvHD Scoring NTDT Iron Burden Estimator Padua RAM PBT (Paediatric BAT)PCNSL MSKCC Score PERC Rule Perioperative Anticoagulation Bridging PESI Score (PE Mortality)PLASMIC Score Platelet Increment Calculator (CCI)PNH Clone Size Interpreter R-IPI (Revised IPI)R-ISS (Revised ISS)Reticulocyte Index (RPI)Revised Geneva Score (PE)Revised Response Criteria (NHL)Revised Zubrod / ECOG Performance Shine & Lal Index Sickle Cell Disease Risk (TCD)SLiM-CRAB Criteria SOKAL Score (CML)Sokal/EUTOS/ELTS Comparison sPESI (Simplified PESI)TACO Risk Score Thalassaemia Transfusion Threshold Thrombocytopaenia Differential Thrombophilia Screening Eligibility Algorithm Time in Therapeutic Range (TTR)TLS Risk Classification Transferrin Saturation Calculator Vienna Prediction Model von Willebrand Factor Activity Interpreter Warfarin Dose Calculator Wells Score (DVT)Wells Score (PE)WHO 2022 AML Classification Mapper WHO Bleeding Scale YEARS Algorithm

Vienna Prediction Model

Vienna Recurrence Model: Validated for both sexes. Requires D-dimer measured ~3 weeks AFTER stopping anticoagulation. 12-month risk > 5% generally favors long-term therapy.

1. Biological Sex

2. Index VTE Site

3. Post-Anticoagulation D-dimer

µg/L (FEU)

Awaiting D-dimer

Guidelines & Evidence

Clinical Details

Section 1

When to Use

Predicting the risk of recurrence in patients with a first unprovoked Venous Thromboembolism (VTE).

Applying to both men and women (unlike the HERDOO2 rule).

Aiding the decision to discontinue anticoagulation after the initial 3–6 month treatment period.

Inclusion Criteria

Patients with a first unprovoked DVT (proximal or distal) or Pulmonary Embolism (PE).

Section 2

Formula & Logic

Variables (Vienna Points)

Factor	Clinical significance
Biological Sex	Men carry a ~2-fold higher risk than women.
VTE Location	Proximal DVT/PE carries higher risk than distal/isolated DVT.
D-dimer Level	Measured 3 weeks after stopping anticoagulation.

The NOMOGRAM Logic

The model utilizes a Cox proportional hazards regression. A cumulative risk of < 5% at 1 year is often used as the threshold for safe discontinuation.

Section 3

Pearls/Pitfalls

D-dimer Variability

The D-dimer MUST be measured ~3 weeks after stopping anticoagulation. Measurement while the patient is still on DOAC/Warfarin will lead to an underestimate of the true recurrence risk.

Distal DVT Escape

Women with isolated distal DVT and a low post-anticoagulation D-dimer have the lowest recorded recurrence rates (~2%), making them the best candidates for stopping lifelong therapy.

Section 4

Evidence Appraisal

Primary Strategy

The Vienna Prediction Model for identifying patients with a low risk of recurrent venous thromboembolism.

Eichinger S et al. • European Heart Journal. 2010;31(13):1676-84.

View Source

Section 5

Literature

Development

Derived by the Vienna Venous Thromboembolism Study group from a prospective cohort of 925 unprovoked VTE patients followed for a median of 43 months.

Last Comprehensive Review: 2026

Guidelines & Evidence

Clinical Details

Section 1

When to Use

Predicting the risk of recurrence in patients with a first unprovoked Venous Thromboembolism (VTE).

Applying to both men and women (unlike the HERDOO2 rule).

Aiding the decision to discontinue anticoagulation after the initial 3–6 month treatment period.

Inclusion Criteria

Patients with a first unprovoked DVT (proximal or distal) or Pulmonary Embolism (PE).

Section 2

Formula & Logic

Variables (Vienna Points)

Factor	Clinical significance
Biological Sex	Men carry a ~2-fold higher risk than women.
VTE Location	Proximal DVT/PE carries higher risk than distal/isolated DVT.
D-dimer Level	Measured 3 weeks after stopping anticoagulation.

The NOMOGRAM Logic

The model utilizes a Cox proportional hazards regression. A cumulative risk of < 5% at 1 year is often used as the threshold for safe discontinuation.

Section 3

Pearls/Pitfalls

D-dimer Variability

The D-dimer MUST be measured ~3 weeks after stopping anticoagulation. Measurement while the patient is still on DOAC/Warfarin will lead to an underestimate of the true recurrence risk.

Distal DVT Escape

Women with isolated distal DVT and a low post-anticoagulation D-dimer have the lowest recorded recurrence rates (~2%), making them the best candidates for stopping lifelong therapy.

Section 4

Evidence Appraisal

Primary Strategy

The Vienna Prediction Model for identifying patients with a low risk of recurrent venous thromboembolism.

Eichinger S et al. • European Heart Journal. 2010;31(13):1676-84.

View Source

Section 5

Literature

Development

Derived by the Vienna Venous Thromboembolism Study group from a prospective cohort of 925 unprovoked VTE patients followed for a median of 43 months.

Last Comprehensive Review: 2026

Related Hematology Tools

Age-adjusted D-dimer Threshold

sPESI

HEP Score

HERDOO2 Rule

Have feedback about this calculator?Let us know.

Vienna Prediction Model

Vienna Recurrence Model: Validated for both sexes. Requires D-dimer measured ~3 weeks AFTER stopping anticoagulation. 12-month risk > 5% generally favors long-term therapy.

1. Biological Sex

2. Index VTE Site

3. Post-Anticoagulation D-dimer

µg/L (FEU)

Awaiting D-dimer

Guidelines & Evidence

Clinical Details

Section 1

When to Use

Predicting the risk of recurrence in patients with a first unprovoked Venous Thromboembolism (VTE).

Applying to both men and women (unlike the HERDOO2 rule).

Aiding the decision to discontinue anticoagulation after the initial 3–6 month treatment period.

Inclusion Criteria

Patients with a first unprovoked DVT (proximal or distal) or Pulmonary Embolism (PE).

Section 2

Formula & Logic

Variables (Vienna Points)

Factor	Clinical significance
Biological Sex	Men carry a ~2-fold higher risk than women.
VTE Location	Proximal DVT/PE carries higher risk than distal/isolated DVT.
D-dimer Level	Measured 3 weeks after stopping anticoagulation.

The NOMOGRAM Logic

The model utilizes a Cox proportional hazards regression. A cumulative risk of < 5% at 1 year is often used as the threshold for safe discontinuation.

Section 3

Pearls/Pitfalls

D-dimer Variability

The D-dimer MUST be measured ~3 weeks after stopping anticoagulation. Measurement while the patient is still on DOAC/Warfarin will lead to an underestimate of the true recurrence risk.

Distal DVT Escape

Women with isolated distal DVT and a low post-anticoagulation D-dimer have the lowest recorded recurrence rates (~2%), making them the best candidates for stopping lifelong therapy.

Section 4

Evidence Appraisal

Primary Strategy

The Vienna Prediction Model for identifying patients with a low risk of recurrent venous thromboembolism.

Eichinger S et al. • European Heart Journal. 2010;31(13):1676-84.

View Source

Section 5

Literature

Development

Derived by the Vienna Venous Thromboembolism Study group from a prospective cohort of 925 unprovoked VTE patients followed for a median of 43 months.

Last Comprehensive Review: 2026

Guidelines & Evidence

Clinical Details

Section 1

When to Use

Predicting the risk of recurrence in patients with a first unprovoked Venous Thromboembolism (VTE).

Applying to both men and women (unlike the HERDOO2 rule).

Aiding the decision to discontinue anticoagulation after the initial 3–6 month treatment period.

Inclusion Criteria

Patients with a first unprovoked DVT (proximal or distal) or Pulmonary Embolism (PE).

Section 2

Formula & Logic

Variables (Vienna Points)

Factor	Clinical significance
Biological Sex	Men carry a ~2-fold higher risk than women.
VTE Location	Proximal DVT/PE carries higher risk than distal/isolated DVT.
D-dimer Level	Measured 3 weeks after stopping anticoagulation.

The NOMOGRAM Logic

The model utilizes a Cox proportional hazards regression. A cumulative risk of < 5% at 1 year is often used as the threshold for safe discontinuation.

Section 3

Pearls/Pitfalls

D-dimer Variability

The D-dimer MUST be measured ~3 weeks after stopping anticoagulation. Measurement while the patient is still on DOAC/Warfarin will lead to an underestimate of the true recurrence risk.

Distal DVT Escape

Women with isolated distal DVT and a low post-anticoagulation D-dimer have the lowest recorded recurrence rates (~2%), making them the best candidates for stopping lifelong therapy.

Section 4